Three independent discounted-cash-flow-style models value UroGen Pharma Ltd. Ordinary Shares every trading day. 0 of 3 currently price URGN above its market price.
| Free Cash Flow model | $-62.84 |
| Excess Profit model | $-56.90 |
| Residual Earnings model | $-0.61 |
| Dividend Discount model | — |
| Piotroski F-Score | 2 / 9 |
| Return on invested capital | -786.1% |
| Net debt / EBITDA | — |
| Gross margin | +88.7% |
| Revenue CAGR | +19.5% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -12.2% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open URGN in StockKitty